Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023

10/12/23 8:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $SGEN alert in real time by email

Seagen Inc. (NASDAQ:SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023.

Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call.

About Seagen

Founded 25 years ago, Seagen Inc. is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. Our colleagues work together with urgency to improve and extend the lives of people living with cancer. An ADC technology trailblazer, approximately one-third of FDA-approved and marketed ADCs use Seagen technology. Seagen is headquartered in Bothell, Washington and has locations in California, Canada, Switzerland and across Europe. For additional information, visit www.seagen.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231012765576/en/

Get the next $SGEN alert in real time by email

Date	Price Target	Rating	Analyst
2/16/2023	$140.00 → $175.00	In-line → Outperform	Evercore ISI
2/16/2023	$155.00 → $175.00	Outperform → Strong Buy	Raymond James
2/6/2023	$162.00 → $141.00	Outperform → Market Perform	SVB Securities
11/21/2022	$135.00	Hold	Truist
10/11/2022	$177.00 → $178.00	Market Perform → Outperform	BMO Capital Markets
6/29/2022	$220.00	Outperform	Raymond James
6/24/2022	$169.00	Market Perform	BMO Capital Markets
2/16/2022	$201.00 → $142.00	Market Outperform	JMP Securities

Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023

Chat with this insight

Recent Analyst Ratings for $SGEN

$SGEN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Seagen Inc. (Amendment)

SEC Form SC 13G/A filed by Seagen Inc. (Amendment)

SEC Form SC 13D/A filed by Seagen Inc. (Amendment)

$SGEN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)

Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)

$SGEN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Seagen upgraded by Evercore ISI with a new price target

Seagen upgraded by Raymond James with a new price target

Seagen downgraded by SVB Securities with a new price target

$SGEN Press Releases

Fastest customizable press release news feed in the world

Alltrna Announces Updates to Its Board of Directors

Pfizer Completes Acquisition of Seagen

Update: Annual Changes to the Nasdaq-100® Index

$SGEN Market Insights

Live Market Insights

$SGEN Leadership Updates

Live Leadership Updates

$SGEN SEC Filings

$SGEN Financials

Live finance-specific insights

Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment

How To Earn $500 A Month From Pfizer Stock

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024

Alltrna Announces Updates to Its Board of Directors

Seagen Appoints Sandra M. Swain, M.D., to Board of Directors

Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

SEC Form 15-12G filed by Seagen Inc.

SEC Form S-8 POS filed by Seagen Inc.

SEC Form S-8 POS filed by Seagen Inc.

Update: Annual Changes to the Nasdaq-100® Index

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

Recent Analyst Ratings for
$SGEN

$SGEN
Large Ownership Changes

$SGEN
Insider Trading

$SGEN
Analyst Ratings

$SGEN
Press Releases

$SGEN
Market Insights

$SGEN
Leadership Updates

$SGEN
SEC Filings

$SGEN
Financials